Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-534-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$375.54 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/25/2019 (Estimated)
OptionableOptionable
GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions
What is GALAPAGOS NV/S's stock symbol?
GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."
How were GALAPAGOS NV/S's earnings last quarter?
GALAPAGOS NV/S (NASDAQ:GLPG) issued its earnings results on Thursday, July, 25th. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by $0.13. The biotechnology company had revenue of $75.96 million for the quarter, compared to analyst estimates of $56.66 million. GALAPAGOS NV/S had a negative net margin of 19.95% and a negative return on equity of 5.45%. View GALAPAGOS NV/S's Earnings History.
When is GALAPAGOS NV/S's next earnings date?
What price target have analysts set for GLPG?
12 brokerages have issued 12-month target prices for GALAPAGOS NV/S's shares. Their forecasts range from $90.00 to $209.00. On average, they expect GALAPAGOS NV/S's stock price to reach $165.56 in the next year. This suggests a possible upside of 5.1% from the stock's current price. View Analyst Price Targets for GALAPAGOS NV/S.
What is the consensus analysts' recommendation for GALAPAGOS NV/S?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GALAPAGOS NV/S.
What are Wall Street analysts saying about GALAPAGOS NV/S stock?
Here are some recent quotes from research analysts about GALAPAGOS NV/S stock:
- 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (9/26/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month, $150 price target on shares of Galapagos is derived from a 13- year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.34, terminal growth rate of -3.0%, risk premium of 4.93%, calculated WACC of 9.3%, and tax rate of 20% beginning in FY 2025. (11%) together make up 88% of our value, with the remainder derived from the probability-adjusted, filgotinib-associated milestone payments." (6/12/2019)
- 3. Cantor Fitzgerald analysts commented, "Our Galapagos thesis: We think that 2019 is the year filgotinib will differentiate itself among the JAKs. We reiterate our Overweight and price target of $130. We expect key Phase 3 data from filgotinib in studies called FINCH 1 and 3 in 1Q19. We think that these data may reveal that filgotinib has an attractive risk/benefit profile among the JAK inhibitors. Section may be found on pages 4 – 5.We value Galapagos shares on a probability-adjusted DCF." (5/2/2019)
Has GALAPAGOS NV/S been receiving favorable news coverage?
Media stories about GLPG stock have been trending somewhat positive on Monday, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. GALAPAGOS NV/S earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for GALAPAGOS NV/S.
Who are some of GALAPAGOS NV/S's key competitors?
Some companies that are related to GALAPAGOS NV/S include Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Mylan (MYL), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF) and Alnylam Pharmaceuticals (ALNY).
What other stocks do shareholders of GALAPAGOS NV/S own?
Who are GALAPAGOS NV/S's key executives?
GALAPAGOS NV/S's management team includes the folowing people:
- Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)
- Mr. Bart Filius MBA, CFO & COO (Age 49)
- Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)
- Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
- Dr. Andre Hoekema, Chief Bus. Officer (Age 62)
When did GALAPAGOS NV/S IPO?
(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.
Who are GALAPAGOS NV/S's major shareholders?
GALAPAGOS NV/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.13%), Henry James International Management Inc. (0.04%), Envestnet Asset Management Inc. (0.03%), Crossmark Global Holdings Inc. (0.01%), Moody National Bank Trust Division (0.01%) and Financial Gravity Wealth Inc. (0.00%).
Which major investors are selling GALAPAGOS NV/S stock?
GLPG stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Financial Gravity Wealth Inc. and Henry James International Management Inc..
Which major investors are buying GALAPAGOS NV/S stock?
GLPG stock was purchased by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Envestnet Asset Management Inc., Pacer Advisors Inc. and Moody National Bank Trust Division.
How do I buy shares of GALAPAGOS NV/S?
Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is GALAPAGOS NV/S's stock price today?
One share of GLPG stock can currently be purchased for approximately $157.52.
How big of a company is GALAPAGOS NV/S?
GALAPAGOS NV/S has a market capitalization of $8.64 billion and generates $375.54 million in revenue each year. The biotechnology company earns $-34,560,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. View Additional Information About GALAPAGOS NV/S.
What is GALAPAGOS NV/S's official website?
How can I contact GALAPAGOS NV/S?
GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]
MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)
MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
